NCT06424834View on ClinicalTrials.gov

Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Angina PectorisMicrovascular AnginaVasospastic AnginaMyocardial Bridge of Coronary Artery
Interventions
DRUG

Amlodipine

Amlodipine taken once orally daily at a starting dose of 2.5mg, uptitrated to a maximum of 10mg if tolerated.

DRUG

Nebivolol

Nebivolol taken once orally daily at a starting dose of 5mg, uptitrated to a maximum of 20mg if tolerated.

DRUG

Placebo

Placebo taken once orally daily.

Trial Locations (1)

94304

RECRUITING

Stanford Hospital, Palo Alto

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Stanford University

OTHER